CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer: a Feasibility Phase II Trial
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs Doxorubicin (Primary)
- Indications Early breast cancer
- Focus Adverse reactions
- 30 Apr 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 30 Apr 2019 Planned primary completion date changed from 30 Nov 2018 to 30 Nov 2019.
- 30 Apr 2019 Status changed from recruiting to active, no longer recruiting.